



2014 UCSF Breast Oncology Program Scientific Retreat

JCCSF, 3200 California St., San Francisco, 94118

Thursday, February 6

12:00-12:30 Atrium

Registration and Boxed Lunch

12:30-4:40 Kanbar Hall

12:30-12:40 Welcome and Introduction to Agenda and Breast Oncology Program
Laura van 't Veer, PhD

Model systems to understand therapeutic response (Moderator: Andrei Goga, MD, PhD)

12:40-1:10 Perspective: Modeling Resistance to Targeted Therapy
Martin McMahon, PhD; Co-Leader, Developmental Therapeutics Program

1:10-1:20 Q&A

1:20-1:40 CDK Inhibitors Block Metastases in Patient Derived Xenograft Models
Devon Lawson, PhD, Postdoctoral Fellow Zena Werb Laboratory

1:40-1:50 Q&A

1:50-2:10 Tumor Metabolism Activity and Therapeutic Response
Luika Timmerman, PhD

2:10-2:20 Q&A

2:20-2:30 Eight Percent of Pink: The Young Patient View (video)
Christine Romer, MBA, BSAC Research Advocate

2:30-2:50 Break

Adaptive Randomization Optimizing Patient Outcome (Moderator: Laura Esserman, MD, MBA)

2:50-3:15 The Model of Adaptive Randomization
Ashish Sanil, PhD, Director & Senior Statistical Scientist, Berry Consultants

3:15-3:25 Q&A

3:25-3:40 How to Find the Patient Matching Therapeutics
Laura van 't Veer, PhD

3:40-3:50 Q&A

3:50-4:15 I-SPY 2 Veliparib Response and Optimal Tumor Subtype
Hope Rugo, MD

4:15-4:25 Q&A

4:25-4:40 Advocate Engagement for Success: Providing the Tools
Susie Brain and Diane Heditsian, BSAC Research Advocates

4:40-6:30 Atrium

California Breast Cancer Research Program Poster Session
(Light refreshments and beverages will be served.)



2014 UCSF Breast Oncology Program Scientific Retreat

JCCSF, 3200 California St., San Francisco, 94118

Friday, February 7

8:30-9:00 Atrium

Registration & Continental Breakfast

9:00-4:00 Kanbar Hall

9:00-9:05 **Welcome & Introduction**

Laura van 't Veer, PhD

HER Targeted Therapies (Moderator: Hope Rugo, MD)

9:05-9:20 Targeting HER2 Cancers, Development of MM302
John Park, MD

9:20-9:35 Taking MM302 in the Clinic, Phase 1 and Biomarker Development
Pamela Munster, MD

9:35-9:45 Q&A

9:45-10:05 Overcoming Resistance to Tyrosine Kinase Inhibition
Mark Moasser, MD

10:05-10:15 Q&A

10:15-10:40 Dual Targeting of HER2

Mark Pegram, MD, Director Breast Cancer Oncology Program, Stanford Cancer Institute

10:40-10:50 Q&A

10:50-11:10 Break

California Breast Cancer Research Program Poster Discussion Session (Moderator: Cathy Park, MD)

11:10-11:20 Presentation of Awards
Marion Kavanaugh-Lynch, MD, MPH, Director, California Breast Cancer Research Program
Carol Simmons, MS, BSAC Research Advocate, Hope Rugo, MD, and Laura van 't Veer, PhD

11:20-11:30 **Detection and Biomarkers Poster: TBN**

11:30-11:40 **Epidemiology and Population Science Poster: TBN**

11:40-11:50 **Physical Science: TBN**

11:50-12:00 *Discussant: member of review committee*

12:00-12:10 *General Discussion and Audience Questions*

12:10-12:20 **Molecular Biology Poster: TBN**

12:20-12:30 **Therapeutics and Clinical Trials Poster: TBN**

12:30-12:40 *Discussant: member of review committee*

12:40-12:50 *General Discussion and Audience Questions*

12:50-1:30 Lunch

Risk Based Patient Management (Moderator: Laura van 't Veer, PhD)

1:30-1:50 Perspective: Implementing Emerging Evidence in Clinical Care: the Athena Network
Laura Esserman, MD, MBA

1:50-2:00 Q&A

2:00-2:20 Translating Research on Mammographic Density to the General Public (video)
Janice Barlow, Executive Director, Zero Breast Cancer

2:20-2:40 Risk-Based Screening, the Model
Martin Eklund, UCSF and Karolinska Institutet, Stockholm, Sweden

2:40-2:50 Q&A

2:50-3:10 The Landscape of Risk Gene Variants
Elad Ziv, MD

3:10-3:20 Q&A

3:20-3:40 Counseling for Variants of Low Risk or Unknown Significance

TBD

3:40-3:50 Q&A

3:50-4:00 Closing Remarks and Adjourn

Laura van 't Veer, PhD